American media sources confirmed that Pfizer will produce, by the end of 2020, about 50 million doses of its vaccine against Corona, instead of 100 million doses due to problems in supplying the necessary materials.
The American “Wall Street” newspaper reported, “We were late. Some shipments of materials, as it turned out, did not meet our standards … We solved this problem, but we will not have time to meet this year’s supply plan,” an informed source was quoted as saying.
“In this case, everything was done at the same time,” he said. “We started work on the supply chain for components last March when the vaccine development was not completed. This is totally unprecedented.”
The newspaper pointed out that companies usually first develop the vaccine and obtain approval for use, and then arrange to supply everything necessary for production, but in the case of “Covid-19”, everything had to be done within a very narrow time frame and prepare for mass production, Without waiting for the vaccine to be developed.
The American “Pfizer” developed a vaccine in partnership with “BioNtech” German, and the drug has been approved for use in Britain, and it is expected that it will soon obtain approval in the European Union and the United States.